title: The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
abstract: The role of both autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) in the management of mantle cell lymphoma (MCL) remains to be clarified. We conducted a consensus project using the RAND-modified Delphi consensus procedure to provide guidance on how SCT should be used in MCL. With regard to autoSCT, there was consensus in support of: autoSCT is the standard first-line consolidation therapy; induction therapy should include high-dose cytarabine and Rituximab; complete or partial remission should be achieved before autoSCT; Rituximab maintenance following autoSCT is not indicated; and omission of autoSCT in 'low-risk' patients is not indicated. No consensus could be reached regarding: autoSCT in the treatment of relapsed disease following non-transplant therapy; the value of positron emission tomography scanning and minimal residual disease (MRD) monitoring; in vivo purging with Rituximab; total body irradiation conditioning for autoSCT; and preemptive Rituximab after autoSCT. For alloSCT, consensus was reached in support of: alloSCT should be considered for patients relapsing after autoSCT; reduced intensity conditioning regimens should be used; allogeneic immunotherapy should be used for MRD eradication after alloSCT; and there is a lack of prognostic criteria to guide the use of alloSCT as first-line consolidation. No consensus was reached regarding the role of alloSCT for relapsed disease following non-transplant therapy.
authors.affiliation: BMT Unit, University Hospital Bristol, Bristol, UK.
authors.forename: S
authors.initials: S
authors.lastname: Robinson
authors.affiliation: University of Heidelberg, Medizinische Klinik, Heidelberg, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Dreger
authors.affiliation: Hospital Clínico Servicio de Hematologica, Salamanca, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Caballero
authors.affiliation: Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Corradini
authors.affiliation: BMT Unit, Rigshospitalet, Copenhagen, Denmark.
authors.forename: C
authors.initials: C
authors.lastname: Geisler
authors.affiliation: Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Ghielmini
authors.affiliation: CHU Nantes, Nantes, France.
authors.forename: S
authors.initials: S
authors.lastname: Le Gouill
authors.affiliation: Department Of Haematology, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Kimby
authors.affiliation: Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth, UK.
authors.forename: S
authors.initials: S
authors.lastname: Rule
authors.affiliation: Department of Oncology and Hematology, 'Città della Salute e della Scienza' University Hospital, Torino, Italy.
authors.forename: U
authors.initials: U
authors.lastname: Vitolo
authors.affiliation: Department of Haemato-Oncology, University of Munich, Munich, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Dreyling
authors.affiliation: Hôpital Necker, Service Hematologie Adulte, Paris, France.
authors.forename: O
authors.initials: O
authors.lastname: Hermine
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D003245:Consensus Statements as Topic; D003561:Cytarabine / Q000008:administration & dosage; D005060:Europe; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D020522:Lymphoma, Mantle-Cell / Q000276:immunology* / Q000628:therapy*; D018365:Neoplasm, Residual; D049268:Positron-Emission Tomography; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods*; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D000069283:Rituximab